• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CBIO

    Catalyst Biosciences Inc.

    Subscribe to $CBIO
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. The company's pipeline also includes a preclinical program partnered with Biogen International GmbH for dry age-related macular degeneration (AMD); factor I protease for SQ prophylaxis in patients with complement factor I deficiency and C4b-degraders designed to target disorders of the classical complement pathway, as well as other complement programs. The company also develops CB 4332 intended for lifelong prophylactic SQ administration in individuals with CFI deficiency; and CB 2782-PEG, a C3 degrader product candidate in preclinical development for the treatment of dry AMD. It has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.

    IPO Year: 2006

    Exchange: NASDAQ

    Website: catalystbiosciences.com

    Peers

    $CPRX

    Recent Analyst Ratings for Catalyst Biosciences Inc.

    DatePrice TargetRatingAnalyst
    11/15/2021Outperform → Market Perform
    Raymond James
    8/6/2021$19.00 → $18.00Outperform
    Raymond James
    See more ratings

    Catalyst Biosciences Inc. SEC Filings

    See more
    • Catalyst Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      2/14/24 5:16:03 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences Inc. filed SEC Form 8-K: Leadership Update, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (Amendment)

      8-K/A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      1/19/24 4:05:30 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits (Amendment)

      8-K/A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      1/12/24 4:01:35 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Catalyst Biosciences Inc.

      8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      12/15/23 4:21:41 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      12/6/23 4:01:15 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form RW filed by Catalyst Biosciences Inc.

      RW - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      11/29/23 4:01:50 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Catalyst Biosciences Inc.

      D - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      11/13/23 5:13:40 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      11/13/23 7:01:19 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Catalyst Biosciences Inc.

      S-3 - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      11/9/23 9:24:20 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      11/6/23 6:06:32 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Catalyst Biosciences Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Catalyst Biosciences downgraded by Raymond James

      Raymond James downgraded Catalyst Biosciences from Outperform to Market Perform

      11/15/21 4:49:07 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James reiterated coverage on Catalyst Biosciences with a new price target

      Raymond James reiterated coverage of Catalyst Biosciences with a rating of Outperform and set a new price target of $18.00 from $19.00 previously

      8/6/21 12:08:01 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens resumed coverage on Catalyst Biosciences with a new price target

      Stephens resumed coverage of Catalyst Biosciences with a rating of Overweight and set a new price target of $19.00 from $18.00 previously

      4/29/21 1:31:07 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James reiterated coverage on Catalyst Biosciences with a new price target

      Raymond James reiterated coverage of Catalyst Biosciences with a rating of Outperform and set a new price target of $19.00 from $18.00 previously

      4/29/21 7:21:22 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James initiated coverage on Catalyst Biosciences with a new price target

      Raymond James initiated coverage of Catalyst Biosciences with a rating of Outperform and set a new price target of $18.00

      3/4/21 2:05:35 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Catalyst Biosciences with a new price target

      Piper Sandler initiated coverage of Catalyst Biosciences with a rating of Overweight and set a new price target of $15.00

      2/10/21 6:20:02 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James reiterated coverage on Catalyst Biosciences with a new price target

      Raymond James reiterated coverage of Catalyst Biosciences with a rating of Outperform and set a new price target of $18.00 from $20.00 previously

      2/4/21 5:20:11 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Catalyst Biosciences Inc. Financials

    Live finance-specific insights

    See more

    Catalyst Biosciences Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Catalyst Biosciences Completes First Steps in Reverse Merger Plan

      Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst") and GNI Group Ltd. (2160.T) ("GNI") today announced that the parties have signed definitive agreements for the sale and purchase of GNI's proprietary new chemical entity F351 program. F351 has shown clinical efficac

      12/27/22 7:00:00 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share

      SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst," the "Company" or "we") today announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the Company's Common Stock previously disclosed by the Company will be September 21, 2022. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. Stockholders of record on the record date who sell their shares prior to the ex-dividend date will not receive the special dividend. The aggregate amount of the payment to be made in connection with this special dividend will be app

      9/1/22 4:05:00 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share

      SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst," the "Company" or "we") today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company's Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend will be approximately $45 million. The Company anticipates that it may declare one or more additional special dividends in the future, although there can be no assurance that such distributions will

      8/25/22 8:00:00 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences Announces Change in Corporate Strategy

      Company to discontinue MarzAA development; focus on developing its complement portfolio Management to host a call today at 8:30 am ET SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced a strategic decision to halt the clinical development of MarzAA, report data to date, and seek a buyer for its hemophilia assets. Catalyst plans to focus its resources on its complement therapeutics and protease medicines platform. The Company also reported its operating and financial results for the third quarter ended September 30, 2021. "We have made a strategic decision to stop the clinical development of MarzAA (engineered FVIIa) an

      11/12/21 7:00:00 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors

      SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Marzeptacog alfa (activated) – or MarzAA, the Company’s subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with Hemophilia A or B with inhibitors that will enter a pivotal Phase 3 study CRIMSON 1 this month. The Fast Track program is designed to facilitate and expedite the development and review of drug candidates that have demonstrated the potential to address an unmet medical need in treating ser

      12/2/20 8:00:00 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Catalyst Biosciences Inc. (Amendment)

      SC 13G/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

      2/14/24 1:18:41 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Catalyst Biosciences Inc. (Amendment)

      SC 13D/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

      1/24/24 5:11:14 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Catalyst Biosciences Inc. (Amendment)

      SC 13D/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

      11/27/23 4:49:38 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Catalyst Biosciences Inc. (Amendment)

      SC 13D/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

      11/1/23 4:58:41 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Catalyst Biosciences Inc. (Amendment)

      SC 13D/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

      10/30/23 7:28:03 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Catalyst Biosciences Inc. (Amendment)

      SC 13G/A - CATALYST BIOSCIENCES, INC. (0001124105) (Subject)

      2/14/23 4:46:13 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Catalyst Biosciences Inc. (Amendment)

      SC 13G/A - CATALYST BIOSCIENCES, INC. (0001124105) (Subject)

      2/14/23 4:09:30 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Catalyst Biosciences Inc. (Amendment)

      SC 13G/A - CATALYST BIOSCIENCES, INC. (0001124105) (Subject)

      2/13/23 2:55:18 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Catalyst Biosciences Inc. (Amendment)

      SC 13G/A - CATALYST BIOSCIENCES, INC. (0001124105) (Subject)

      2/13/23 12:06:21 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Catalyst Biosciences Inc. (Amendment)

      SC 13D/A - CATALYST BIOSCIENCES, INC. (0001124105) (Subject)

      10/7/22 7:45:06 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Catalyst Biosciences Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

      EMERYVILLE, Calif., Dec. 15, 2023 /PRNewswire/ -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio. Neil Dhawan, Ph.D, Totus co-founder, founding CEO, and CSO, will transition into a new role as CSO and Head of R&D, where he will continue to oversee the company's platform, programs, and data. "We are thrilled by Nassim's arrival," said DCVC Bio Managing Pa

      12/15/23 9:04:00 AM ET
      $CBIO
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

      The combined company will operate as "Gyre Therapeutics, Inc." with its common stock traded on Nasdaq under trading symbol "GYRE" effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst") today announced completion of the business combination with GNI Group Ltd. and related entities. Catalyst received stockholder approval for all proposals necessary to complete the business combination at a special meeting of stockholders held on August 29, 2023. Catalyst effected a name change and a reverse stock split of Catalyst's common stock immediately prior to the closing of the business combination. The combined company w

      10/30/23 12:00:00 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences Provides Corporate Update

      SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ:CBIO) ("Catalyst" or "the Company") today provided two corporate updates. In connection with the Company's previously announced asset purchase agreement with GNI Group Ltd ("GNI Group") and GNI Hong Kong Limited (together "GNI") to purchase all of the assets and intellectual property rights primarily related to GNI's proprietary hydronidone compound outside of China (collectively, the "F351 Assets"), and the definitive agreement with GNI and other minority stockholders to purchase their controlling interest in Beijing Continent Pharmaceutical Co. Ltd., a commercial-stage pharmaceutical company

      2/28/23 8:00:00 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology

      Entered into an acquisition deal of 3 programsYONGIN, South Korea, Feb. 27, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ:CBIO) to acquire 3 programs related to the orphan hematology disorders. This agreement will bring to GC Biopharma 3 programs, including "Marzeptacog alfa (MarzAA)", an engineered factor VIIa which is ready for Phase 3 clinical stage development. In its previous clinical development trials, "

      2/27/23 7:53:00 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences Completes First Steps in Reverse Merger Plan

      Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst") and GNI Group Ltd. (2160.T) ("GNI") today announced that the parties have signed definitive agreements for the sale and purchase of GNI's proprietary new chemical entity F351 program. F351 has shown clinical efficac

      12/27/22 7:00:00 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share

      SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst," the "Company" or "we") today announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the Company's Common Stock previously disclosed by the Company will be September 21, 2022. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. Stockholders of record on the record date who sell their shares prior to the ex-dividend date will not receive the special dividend. The aggregate amount of the payment to be made in connection with this special dividend will be app

      9/1/22 4:05:00 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share

      SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst," the "Company" or "we") today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company's Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend will be approximately $45 million. The Company anticipates that it may declare one or more additional special dividends in the future, although there can be no assurance that such distributions will

      8/25/22 8:00:00 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation

      SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst," the "Company" or "we") today announced that JDS1, LLC, one of the Company's stockholders, has dismissed its lawsuits against the Company. "With the JDS1 litigation behind us, the Board of Directors will be meeting to determine the details of an initial distribution of capital, and we will communicate this information to shareholders shortly," said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. In addition to dismissing its lawsuits against the Company, JDS1 and certain of its affiliates have agreed to a customary standstill and voting commitment, and

      8/19/22 8:00:00 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results

      SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the "Company" or "we") today announced its operating and financial results for the second quarter ended June 30, 2022. "We were very pleased to have completed the sale of our complement portfolio during the second quarter to Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ("Vertex") for $60.0 million in cash with up to $5.0 million of that amount due in May 2023. This transaction was the result of a comprehensive and competitive review of strategic alternatives led by the Company's Board of Directors (the "Board"), management team and independent legal and financial advisors," said N

      8/15/22 4:05:00 PM ET
      $CBIO
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JDS1, LLC Terminates Proxy Contest at Catalyst's 2022 Annual Meeting

        JDS1, LLC ("JDS1"), which collectively with the other reporting persons in its Section 13(d) group, beneficially owns approximately 8.4% of the outstanding common stock of Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst" or the "Company"), commented today on its previously announced withdrawal of the director nominations and other proposed business that it had intended to bring before the upcoming 2022 Annual Meeting of Stockholders of Catalyst Biosciences, Inc. As previously disclosed last week in its public filings with the Securities and Exchange Commission, JDS1 has withdrawn its nominations of candidates for election to the Catalyst Board of Directors at Catalyst's Annual Meeti

      8/11/22 6:00:00 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Catalyst Biosciences Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Luo Ying acquired 2,840,376 shares (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/22/23 7:55:53 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Ye Weiguo

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/22/23 7:49:12 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Ma Songjiang

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/22/23 7:40:34 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chen Ruoyu

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/22/23 7:34:30 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gni Group Ltd. acquired 63,588,119 shares (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/22/23 7:27:22 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Wu Charles C

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/22/23 7:20:00 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Ma Songjiang claimed ownership of 2,942,467 shares (SEC Form 3) (Amendment)

      3/A - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/22/23 7:06:49 PM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Luo Ying

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/1/23 6:15:35 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Eastling Thomas Wilson

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/1/23 6:15:33 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Usman Nassim

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/1/23 6:15:26 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Catalyst Biosciences Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

      EMERYVILLE, Calif., Dec. 15, 2023 /PRNewswire/ -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio. Neil Dhawan, Ph.D, Totus co-founder, founding CEO, and CSO, will transition into a new role as CSO and Head of R&D, where he will continue to oversee the company's platform, programs, and data. "We are thrilled by Nassim's arrival," said DCVC Bio Managing Pa

      12/15/23 9:04:00 AM ET
      $CBIO
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences Sends Letter to Stockholders

      Reiterates the Board's Commitment to Expeditiously Distributing All of the Company's Available Cash to Stockholders, Net of Liabilities and Obligations Warns Stockholders that JDS1 May Have Ulterior Motives in Running a Proxy Contest: Gaining Control of the Company's Cash and Other Assets for JDS1's Own Benefit Stockholders Urged to VOTE "FOR" ALL of Catalyst's Nominees, Who Are Committed to the Company's Cash Distribution Plan, on the WHITE Proxy Card SOUTH SAN FRANCISCO, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the "Company" or "we") today announced that it mailed a letter to its stockholders in connection with the Company's upcoming 2022 Ann

      7/19/22 8:00:00 AM ET
      $CBIO
      $EVOL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      EDP Services
      Technology
    • ShouTi Appoints Sharon Tetlow to Board of Directors

      ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today announced the appointment of Sharon Tetlow to the company's board of directors. Ms. Tetlow will also serve as chair of the audit committee. "On behalf of the board and management team at ShouTi, I am pleased to welcome Sharon to the board," said Daniel Welch, Chairman of the Board, ShouTi. "Sharon is an accomplished life sciences finance executive whose deep financial strategy and compliance expertise will be instrumental in leading our audit committee. With an outstanding track record of advising biopharmaceutical companies, Sharon's perspectiv

      3/29/22 8:00:00 AM ET
      $CBIO
      $DICE
      $VALN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Catalyst Biosciences Announces Appointment of Jeanne Jew to its Board of Directors

      Seasoned Biopharmaceutical Executive Adds Substantial Corporate Development Expertise SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced the appointment of Jeanne Jew to its Board of Directors. "We are delighted to welcome Jeanne to our Board of Directors. Jeanne's deep corporate development expertise will be a tremendous asset as we advance our Protease Medicines pipeline," said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. Ms. Jew commented, "I look forward to supporting the company's continued growth and working with the team on its strategic planning and business development initiatives.

      9/8/21 8:00:00 AM ET
      $CBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care